Second Quarter 2023 Financial Results & Business Update August 2, 2023 ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Colleen Kusy - Baird Nicole Gabreski - Piper Sandler Brian Abrams - RBC Capital Markets Operator Good m ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning. My name is ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank Maurice Raycroft - Jefferies Nicole Gabreski - Piper Sandler & Co. Michael Ulz - Morgan Stanley Edward White - H.C. Wainwright & Co. Eric ...

1 ©2023 KARYOPHARM THERAPEUTICS INC. Karyoph Fourth Quarter and Full Year 2022 Financial Results & Business Update February 15, 2023 On Today's Call • Welcome Elhan Webb, CFA, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Pauls ...

1 ©2023 KARYOPHARM THERAPEUTICS INC. 3) Karyoph A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies JP MORGAN 2023 HEALTHCARE CONFERENCE January 11, 2023 2 ©2023 KARYOPHARM THERAPEUTICS INC. Richard Paulson Chief Executive Officer OVERVIEW 400 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Abi Gray - R.W. Baird Brian Abrahams - RBC Capital Markets Eric Joseph - JPMorgan Operator Good afternoon. ...